LongBio-B Surges 55.63% on Listing Debut at HK$149.5

NewTimeSpace · 2026/06/05 09:45 · By Zehong Cheng

NewTimeSpace News: LongBio-B was listed on HKEX Main Board on the day. As of press time, the stock traded at HK$149.5, climbing HK$53.44 or 55.63% against the IPO offer price of HK$96.06. It is the sole gainer among three newly-listed stocks debuting today.

NewTimeSpace News: LongBio-B (01779.HK) made its official Main Board debut on the Hong Kong Stock Exchange on June 5, 2026. As of press time, the share was quoted at HK$149.5, an increase of HK$53.44, representing a 55.63% rise from the final offer price of HK$96.06 per share.

The IPO subscription period spanned May 28 to June 2, with final pricing set at HK$96.06 apiece. The company globally offered roughly 14.19 million H-shares in total, with each board lot consisting of 50 shares and a per-lot entry cost of HK$4,851.44. Net IPO proceeds reached approximately HK$1.255 billion.

A clinical-stage biopharmaceutical firm, Tianchen Biotech focuses on therapies for allergic and autoimmune diseases, with its flagship asset LP-003 being an anti-IgE antibody. Among the three new listings launched on the same day, Tianchen Biotech is the only stock closing in positive territory.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

LongBio-B IPO ListingDebut